Dimensional Fund Advisors LP Acquires 372,196 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Dimensional Fund Advisors LP lifted its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 35.3% during the 4th quarter, Holdings Channel reports. The firm owned 1,425,960 shares of the company’s stock after purchasing an additional 372,196 shares during the period. Dimensional Fund Advisors LP’s holdings in Kura Oncology were worth $12,419,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Harbor Advisors LLC acquired a new position in Kura Oncology in the 4th quarter valued at $87,000. E Fund Management Co. Ltd. bought a new stake in Kura Oncology during the fourth quarter worth about $90,000. Optimize Financial Inc acquired a new stake in Kura Oncology during the fourth quarter worth about $100,000. Corient Private Wealth LLC bought a new position in Kura Oncology in the 4th quarter valued at about $109,000. Finally, Teacher Retirement System of Texas raised its position in shares of Kura Oncology by 19.9% in the 4th quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company’s stock valued at $120,000 after buying an additional 2,285 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on KURA shares. StockNews.com cut shares of Kura Oncology from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. Wedbush reiterated an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Tuesday, April 8th. BTIG Research downgraded Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a research report on Monday, April 28th. Finally, Cantor Fitzgerald raised shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.89.

Kura Oncology Stock Down 3.8 %

Shares of NASDAQ KURA opened at $5.77 on Friday. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $23.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm has a market cap of $499.54 million, a PE ratio of -2.44 and a beta of 0.50. The company has a 50 day simple moving average of $6.57 and a 200 day simple moving average of $9.23.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15). The firm had revenue of $14.11 million for the quarter, compared to the consensus estimate of $39.08 million. On average, research analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.